Home > Search Results
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1

Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation

Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis: A Systematic Review and Economic Evaluation

Health Technology Assessment - NIHR Evaluation, Trials and Studies Coordinating Centre (UK)

Version: February 2011

Background

Psoriatic arthritis (PsA) is defined as a unique inflammatory arthritis affecting the joints and connective tissue, and is associated with psoriasis of the skin or nails. There are difficulties in estimating its prevalence due to the lack of a precise definition and diagnostic criteria for PsA. The prevalence of psoriasis in the general population has been estimated at between 2% and 3%, and the prevalence of inflammatory arthritis in patients with psoriasis has been estimated to be up to 30%. PsA affects males and females equally, with a worldwide distribution. Figures for the UK have estimated the adjusted prevalence of PsA in the primary care setting to be 0.3%, based on data from north-east England involving six general practices, covering a population of 26,348. Another study reported PsA prevalence rates per 100,000 of 3.5 for males and 3.4 for females, based on data from 77 general practices in the Norwich Health Authority, with a population of 413,421. Severe PsA with progressive joint lesions can be found in at least 20% of patients with psoriasis.

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...